Is the middle ground news could be good could be bad mean we are getting played??
Know what you hold ….. If you don’t do any DD then you are gambling however if you trust in a company you don’t know much about or the ppl who lead it why are you staying history has shown they can’t seem to complete a merger
Caution is a for real statement ???
This is a shorts dream ….. stock
I’ll buy more once it’s back in the .60c range
Meanwhile little to NO insider buys that would go a LONG way for proof of growth & trajectory
However it’s looking like a pos scam
Pure lies
Evil
This is DEAD
Held gains ✅
PR Drops this 1.4 Micro Free float runs
My Shares at set at 18.00 to sell 1/2 my 50,112 shares the other 1/2 is set higher
We got the RUG pull drop and today I would call it the grind it out rise with above avg VOL but nothing like a great Merger PR drop will do
GL yall we eat tomorrow
Apextradez where winning is made easy off 15yrs of skills
The “Corp action” from Fridays finalized merger documents will be “offical within 3-4” days per the Sec requirements News Drops Monday after the Bell be ready for a DROP into the LOW 1.30 - 1.77 Buy Zone were insiders will buy the Float Shorts will try to make one last run off PUTTs and then 9:30 after the Bell the news drops this has history of STRONG Spikes my shares are locked in Sell points already in case of HALTS this hits 18- 34.00 but settles over 60.00 and then Drops back into the 12 - 16.00 range
Apextradez is were Alpha.Scorpio shares his deep dive into to those who gain access
Lets go NIVF
PRESENTATION DETAILS:
• TITLE: NOCISCAN, Augmented Intelligence, and Low Back Pain Decision Support
• PRESENTER: Dr. Nicholas Theodore
• DATE: Friday, February 21, 2025
• TIME: 1:15 PM EST
• LOCATION: JW Marriott Tampa Water Street
Apextradez…. Com where it all happens where we win daily
Phio Pharmaceuticals Corp. is scheduled to
present today, February 4, 2025, at
2:00 pm EST during the Renmark
Financial Communications Virtual
Non-Deal Roadshow Series. Robert
Bitterman, the company's CEO and
Chairman, will discuss Phio's
proprietary INTASYL siRNA
technology and the ongoing clinical
trial of their lead compound,
PH-762, aimed at treating skin cancers.
When is merger news coming
